APA citiranje

Yoshida, K., & Yamada, Y. (2015). Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations (JO25567): An open-label, randomized, multicenter, phase II study. Transl Lung Cancer Res.

Citação norma Chicago

Yoshida, Kazushi, and Yasuhide Yamada. "Erlotinib Alone or With Bevacizumab As First-line Therapy in Patients With Advanced Non-squamous Non-small-cell Lung Cancer Harboring EGFR Mutations (JO25567): An Open-label, Randomized, Multicenter, Phase II Study." Transl Lung Cancer Res 2015.

MLA citiranje

Yoshida, Kazushi, and Yasuhide Yamada. "Erlotinib Alone or With Bevacizumab As First-line Therapy in Patients With Advanced Non-squamous Non-small-cell Lung Cancer Harboring EGFR Mutations (JO25567): An Open-label, Randomized, Multicenter, Phase II Study." Transl Lung Cancer Res 2015.